Taro Pharma agrees to buyout offer from India's Sun Pharma
Aug 12 (Reuters) - Taro Pharmaceutical Industries said late on Sunday it has agreed to be taken private by Sun Pharmaceutical Industries, weeks after it rejected an earlier $367 million bid from the Indian drugmaker.
All shareholders of Taro other than Sun Pharmaceutical and its affiliates will receive a cash payment of $39.50 per share upon the closing of the deal, according to the terms released.
Sun Pharmaceutical had earlier offered $24.50 per share, which was subsequently rejected by Taro.
Sun Pharmaceutical and its affiliates collectively own about 66 percent of the outstanding Taro ordinary shares and 100 percent of the shares of Taro's founders, representing about 77.5 percent of the outstanding voting power in Taro.
Based on 44.5 million shares outstanding, according to Reuters data, the one-third stake to be bought out by Sun Pharmaceutical is valued at $571.3 million.
The deal was approved by Taro's board of directors, the company said. Shares of Taro closed at $41.10 Friday on the New York Stock Exchange.
- Tweet this
- Share this
- Digg this
- Google launches $105 Android One; eyes low-price smartphone boom
- Pakistani Islamists use floods to turn opinion against India
- Boeing, SpaceX win contracts to build 'space taxis' for NASA |
- Iraqi official briefs Syria's Assad on efforts against Islamic State
- Citing security threat, Obama expands U.S. role fighting Ebola
The electricity board in this Indian city has been instructed to avoid any power cuts and officials have been told to have their shoes polished and their shirts tucked in: Nothing has been left to chance for this week's visit by Chinese President Xi Jinping. Full Article
Climate smart farmers get tech savvy to save India's bread basket. Full Article